Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476202 · ClinicalTrials.gov registry record · Phase 2
Provoked Craving Relief Study by NRT
A Phase 2 study of Smoking Cessation, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT01476202 is a Phase 2 study of Smoking Cessation that has completed, run by GlaxoSmithKline. The registered enrollment target is 120 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01476202, a Phase 2 study of Smoking Cessation, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to assess the ability of the mint nicotine mouth strip to relieve provoked cigarette craving in light smokers compared to nicotine lozenge and nicotine gum.
Conditions Studied
Interventions
- DRUG nicotine
Study Locations (1)
Kentucky
- Central Kentucky Research Associates, Inc. - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01476202
The ClinicalTrials.gov registry entry for NCT01476202 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (75% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which nicotine is the first listed.
NCT01476202 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT01476202 about?
NCT01476202 is a clinical study titled "Provoked Craving Relief Study by NRT". This study is designed to assess the ability of the mint nicotine mouth strip to relieve provoked cigarette craving in light smokers compared to nicotine lozenge and nicotine gum.
What is the current status of trial NCT01476202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2011-11. Estimated completion is 2012-01.
What conditions does trial NCT01476202 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT01476202?
The interventions under investigation include: nicotine (DRUG).
Who is sponsoring clinical trial NCT01476202?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01476202 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
RECRUITING · Phase 2
-
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
COMPLETED · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Suvorexant to Reduce Symptoms of Nicotine Use
COMPLETED · Phase 2
-
Pharmacogenetics, Emotional Reactivity and Smoking
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.